Gottlieb continues to be Trump’s leading candidate for FDA; BeyondSpring completes unusual IPO

→ Scott Gottlieb is President Trump’s leading choice for FDA commissioner, Bloomberg now reports, citing “people” familiar with the matter. BioCentury had the scoop in mid-February.

→ BeyondSpring, a biotech with deep roots in China, has completed an unusual IPO this week. After initially targeting an offering designed to raise $100 million, the biotech ended up selling 174,286 shares at $20 and then executed a private offering to insiders for another 2.5 million shares. The total amounted to $54 million. The company has a cancer drug in several studies.

→ The FDA has extended Radius Health’s PDUFA date on Abaloparatide-SC by three months. The new deadline is June 30.

→ Pharnext has agreed to combine its platform tech with Galapagos’ preclinical drug candidates to create new drug combos. “Pharnext has already obtained promising clinical results with its cutting-edge technology, which has encouraged us to collaborate,” said Galapagos CEO Onno van de Stolpe. “We are very pleased to collaborate with Pharnext and to benefit from Pharnext’s expertise in deciphering diseases’ molecular networks. We hope that this will reinforce Galapagos’ R&D capabilities to generate new therapeutic approaches in a highly efficient and modern manner.”


Get Endpoints News in your inbox

News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Quick Subscribe

You're subscribing to Endpoints News

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy

EvaluatePharma World Preview 2017